Delivery Order SPE2DB20D2014-SPE2DB25FB76V

Award Date 4/28/25
Potential Completion Date 4/29/25
Potential Value $2.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,357.54 Firm Fixed Price Delivery Order contract is for the supply of 4,567,599,451 units of Candesartan Cilexetil 8 mg tablets. The contract has an ultimate completion date of March 18, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,089.38 firm fixed-price delivery order is for the supply of 90-count bottles of 32mg Candesartan Cilexetil tablets. The contract has an ultimate completion date of October 10, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award from the Defense Logistics Agency (DLA) was made to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,840.66 Firm Fixed Price delivery order contract is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of July 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical which serves as a primary vehicle...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of 4,566,514,819 units of Candesartan Cilexetil 32 mg tablets. The firm-fixed-price delivery order, valued at $2,264.64, has a completion date of November 22, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,854.92, is a delivery order for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of March 21, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract, valued at $3,734.76, is for the supply of Candesartan Cilexetil 8 mg tablets. The contract has an ultimate completion date of April 23, 2025 and is a firm fixed-price, non-set-aside award. AmerisourceBergen Drug Corporation holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,368.68, is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of April 1, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,804.08 firm fixed-price delivery order is for the supply of 4,567,304,182 units of the generic medication Candesartan Cilexetil 16 mg tablets, with a completion date of February 19, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award, valued at $7,570.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 16 mg tablets, a cardiovascular medication. This is a firm fixed-price delivery order contract that will run through January 14, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,875.50, is for the delivery of Candesartan Cilexetil 16 mg tablets. It is a firm fixed price delivery order contract that does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB25FB76V
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,765.44 firm fixed-price delivery order is for the supply of Candesartan Cilexetil 16 mg tablets with an ultimate completion date of April 29, 2025.

Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support vehicle with a performance period through December 2026. This enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The current delivery order is not set aside and represents open competition.

Generated 7/28/25, 11:10 AM